Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Global ESG and Sustainability Update: Reporting & Due Diligence Developments and Compliance StrategiesTuesday, May 19, 2026Sidley Advises on Galaxy Digital’s US$500 Million At-the-Market Equity ProgramMay 14, 2026Sidley Represents J.S. Held in Acquisitions of Clark Seif Clark and CMMMay 13, 2026Texas Corporate Litigation Reforms Take Hold: Federal Court Enforces Texas’s 3% Ownership Requirement for Derivative ClaimsMay 12, 2026Sidley Represents Lido Advisors in Its Partnership With Jackson Hole Capital PartnersMay 12, 2026Sidley Represents VoltaGrid in Acquisition of Propell Energy Technology LimitedMay 12, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory